Norges Bank Sarepta Therapeutics, Inc. Transaction History

Norges Bank

$736 Billion
Q4 2024

A detailed history of Norges Bank transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Norges Bank holds 1,038,861 shares of SRPT stock, worth $111 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,038,861

Holding current value

$111 Million

% of portfolio

0.02%

49 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$104.54 - $137.94 $109 Million - $143 Million	1,038,861 New	1,038,861 $126 Million
Q2 2024 Aug 14, 2024	BUY	$113.33 - $163.85 $105 Million - $151 Million	924,428 New	924,428 $146 Million
Q4 2023 Feb 09, 2024	BUY	$67.31 - $124.76 $56.3 Million - $104 Million	836,849 New	836,849 $80.7 Million
Q3 2023 Nov 13, 2024	BUY	$102.5 - $123.59 $83.3 Million - $100 Million	812,965 New	812,965 $98.5 Million
Q3 2023 Nov 13, 2023	SELL	$102.5 - $123.59 $85.7 Million - $103 Million	-836,318 Closed	0 $0
Q2 2023 Aug 14, 2024	SELL	$106.4 - $157.19 $9.98 Million - $14.7 Million	-93,804 Reduced 10.15%	830,624 $95.1 Million
Q2 2023 Aug 14, 2023	SELL	$106.4 - $157.19 $79.4 Million - $117 Million	-746,132 Closed	0 $0
Q1 2023 May 15, 2024	BUY	$117.53 - $155.99 $90 Million - $119 Million	766,010 New	766,010 $106 Million
Q4 2022 Feb 14, 2023	BUY	$100.86 - $132.13 $87.1 Million - $114 Million	863,721 New	863,721 $112 Million
Q3 2022 Nov 13, 2023	BUY	$75.71 - $119.24 $63.3 Million - $99.7 Million	836,318 New	836,318 $92.4 Million
Q2 2022 Aug 14, 2023	BUY	$62.69 - $88.44 $46.8 Million - $66 Million	746,132 New	746,132 $55.9 Million
Q1 2022 May 12, 2023	SELL	$63.15 - $90.42 $11.1 Million - $15.8 Million	-175,132 Reduced 20.28%	688,589 $53.8 Million
Q1 2022 May 09, 2022	SELL	$63.15 - $90.42 $41.3 Million - $59.2 Million	-654,753 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$77.28 - $99.42 $50.6 Million - $65.1 Million	654,753 New	654,753 $59 Million
Q3 2021 Nov 14, 2022	BUY	$65.97 - $92.48 $41.9 Million - $58.8 Million	635,708 New	635,708 $58.8 Million
Q3 2021 Nov 05, 2021	SELL	$65.97 - $92.48 $43.6 Million - $61.1 Million	-660,271 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$69.38 - $86.75 $45.8 Million - $57.3 Million	660,271 New	660,271 $51.3 Million
Q2 2021 Aug 10, 2021	SELL	$69.38 - $86.75 $46.8 Million - $58.5 Million	-674,002 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$72.25 - $168.95 $48.7 Million - $114 Million	674,002 New	674,002 $50.2 Million
Q1 2021 May 07, 2021	SELL	$72.25 - $168.95 $33.8 Million - $79 Million	-467,754 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$125.56 - $178.74 $58.7 Million - $83.6 Million	467,754 New	467,754 $79.7 Million
Q4 2020 Feb 10, 2021	SELL	$125.56 - $178.74 $62.6 Million - $89.2 Million	-498,866 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$127.12 - $172.34 $63.4 Million - $86 Million	498,866 New	498,866 $70.1 Million
Q3 2020 Nov 10, 2020	SELL	$127.12 - $172.34 $71.4 Million - $96.8 Million	-561,630 Closed	0 $0
Q2 2020 Aug 13, 2021	BUY	$93.0 - $171.7 $52.2 Million - $96.4 Million	561,630 New	561,630 $90.1 Million
Q2 2020 Aug 07, 2020	SELL	$93.0 - $171.7 $53.6 Million - $98.9 Million	-576,123 Closed	0 $0
Q1 2020 May 07, 2021	BUY	$82.38 - $131.64 $47.5 Million - $75.8 Million	576,123 New	576,123 $56.4 Million
Q1 2020 May 08, 2020	SELL	$82.38 - $131.64 $47.5 Million - $75.8 Million	-576,123 Closed	0 $0
Q4 2019 Mar 03, 2020	BUY	$76.53 - $135.58 $44.1 Million - $78.1 Million	576,123 New	576,123 $74.3 Million
Q4 2019 Feb 12, 2020	SELL	$76.53 - $135.58 $38.4 Million - $67.9 Million	-501,123 Closed	0 $0
Q3 2019 Nov 13, 2020	BUY	$72.81 - $156.91 $36.5 Million - $78.6 Million	501,123 New	501,123 $37.7 Million
Q3 2019 Nov 08, 2019	SELL	$72.81 - $156.91 $35.4 Million - $76.4 Million	-486,601 Closed	0 $0
Q2 2019 Aug 13, 2020	BUY	$112.21 - $151.95 $54.6 Million - $73.9 Million	486,601 New	486,601 $73.9 Million
Q2 2019 Aug 09, 2019	SELL	$112.21 - $151.95 $62.3 Million - $84.4 Million	-555,196 Closed	0 $0
Q1 2019 May 11, 2020	BUY	$106.67 - $151.68 $2.64 Million - $3.75 Million	24,716 Added 4.66%	555,196 $66.2 Million
Q4 2018 Mar 04, 2019	BUY	$97.32 - $148.76 $51.6 Million - $78.9 Million	530,480 New	530,480 $57.9 Million
Q4 2018 Feb 08, 2019	SELL	$97.32 - $148.76 $44.2 Million - $67.5 Million	-453,871 Closed	0 $0
Q3 2018 Nov 12, 2019	BUY	$115.31 - $161.51 $52.3 Million - $73.3 Million	453,871 New	453,871 $73.3 Million
Q3 2018 Nov 09, 2018	SELL	$115.31 - $161.51 $47 Million - $65.8 Million	-407,514 Closed	0 $0
Q2 2018 Aug 12, 2019	BUY	$71.74 - $153.69 $29.2 Million - $62.6 Million	407,514 New	407,514 $53.9 Million
Q2 2018 Jul 23, 2018	SELL	$71.74 - $153.69 $33.5 Million - $71.8 Million	-467,133 Closed	0 $0
Q1 2018 May 15, 2019	BUY	$54.02 - $82.27 $25.2 Million - $38.4 Million	467,133 New	467,133 $34.6 Million
Q1 2018 May 09, 2018	SELL	$54.02 - $82.27 $26.4 Million - $40.2 Million	-488,034 Closed	0 $0
Q4 2017 Mar 05, 2018	BUY	$47.64 - $56.75 $23.2 Million - $27.7 Million	488,034 New	488,034 $27.2 Million
Q4 2017 Feb 09, 2018	SELL	$47.64 - $56.75 $28.2 Million - $33.6 Million	-592,028 Closed	0 $0
Q3 2017 Nov 13, 2018	BUY	$35.73 - $47.15 $21.2 Million - $27.9 Million	592,028 New	592,028 $26.9 Million
Q3 2017 Nov 07, 2017	SELL	$35.73 - $47.15 $20.5 Million - $27 Million	-573,205 Closed	0 $0
Q1 2017 May 11, 2018	BUY	N/A	231,952 Added 67.97%	573,205 $17 Million
Q3 2016 Nov 13, 2017	BUY	N/A	341,253	341,253 $0

Others Institutions Holding SRPT

# of Institutions

535

Shares Held

87.4M

Call Options Held

1.55M

Put Options Held

1.35M

Black Rock Inc. New York, NY

10.3M
Shares

$1.1 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

9.09M
Shares

$970 Million
0.02% of portfolio
Capital International Investors Los Angeles, CA

8.7M
Shares

$928 Million
0.21% of portfolio
Janus Henderson Group PLC London, X0

4.33M
Shares

$462 Million
0.28% of portfolio
State Street Corp Boston, MA

4.07M
Shares

$434 Million
0.02% of portfolio

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $9.35B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Account